The FDA overstepped its authority when it issued a rule last May to bring laboratory-developed tests under the agency’s ...

Vertex lost a legal battle against the federal government on Monday over its proposed fertility support program that would ...

Vaxcyte’s stock price dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an ...

As­traZeneca has great am­bi­tions for its mid-stage oral cho­les­terol drug, be­liev­ing that it could reach peak sales of ...

A New York City drug developer led by well-known executives and backed by some of the top names in biotech investing is ...

Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing ...

FDA biologics chief Peter Marks resigns over vaccine dispute with HHS Secretary RFK Jr., causing biotech stocks to drop.

Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survival outcomes in a late-stage test in patients ...

Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...

BiomX's BX211 virus therapy shows promise in Phase 2 trial, reducing foot ulcer size in diabetic bone infection patients ...

Heart gene therapy maker Tenaya Therapeutics is laying off 30% to 40% of its staff by the end of the year, the company’s CEO Faraz Ali told Endpoints News by email.

Transcend Therapeutics’ PTSD treatment succeeded in a mid-stage study, propelling the scrappy company of less than 20 people toward a Phase 3 study that could begin at the start of next year.